SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...

Invitae has launched a cancer blood test designed to detect the minimal residual disease left over from solid tumors to help gauge a patient’s risk of recurrence and track their response to treatments ...

Invitae (NYSE: NVTA) recently announced news that made its shares pop. The genetic testing company won a regulatory nod for a first-of-its-kind test for hereditary cancer risk. The U.S. Food and Drug ...

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it met its volume guidance of 17,000-19,000 billable tests delivered in 2015, ...

Genetic testing company Invitae has begun making its screening programs available at no charge for conditions including muscular dystrophy, prostate cancer, cardiomyopathy, arrhythmia and lysosomal ...

SAN FRANCISCO, April 20, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced the addition of 80 new panels alongside ...

The long term profitability and success of any company is highly dependent on the market in which it operates. Many markets have low barriers to entry; many sellers offer undifferentiated products, ...

San Francisco-based genetic testing company Invitae has rolled out a one-price-fits-all payment model for its range of tests, charging a set $475 for any test for patients who don’t go through their ...

Invitae’s revenue has climbed over time thanks to a vast portfolio of genetic tests. At the same time, the company has struggled to turn that into profitability. Invitae shares have dropped more than ...